 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- ACTM-838 / Actym Therap
Bulk and single-cell analysis of tumor microenvironment (TME) reprogramming induced via ACTM-838, a systemically administered microbial-based clinical-stage immunotherapy (Grand Ballroom AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1748;
IV-delivered ACTM-838 is currently being evaluated in a phase 1 clinical trial. Ethics Approval All animals were used according to protocols approved by an Institutional Animal Care and Use Committee and maintained in specific pathogen-free conditions in a AAALAC accredited barrier facility.
- ACTM-838 / Actym Therap
Bulk and single-cell analysis of tumor microenvironment (TME) reprogramming induced via ACTM-838, a systemically administered microbial-based clinical-stage immunotherapy (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_630;
IV-delivered ACTM-838 is currently being evaluated in a phase 1 clinical trial. Ethics Approval All animals were used according to protocols approved by an Institutional Animal Care and Use Committee and maintained in specific pathogen-free conditions in a AAALAC accredited barrier facility.
- || ACTM-838 / Actym Therap
Enrollment open, Metastases: ACTM-838-01: A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 10, 2024
P1, N=35, Recruiting, Sponsor: Actym Therapeutics, Inc.
Ethics Approval All animals were used according to protocols approved by an Institutional Animal Care and Use Committee and maintained in specific pathogen-free conditions in a AAALAC accredited barrier facility. Not yet recruiting --> Recruiting
- | ACTM-838 / Actym Therap
New P1 trial, Metastases: ACTM-838-01: A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 27, 2024
P1, N=35, Not yet recruiting, Sponsor: Actym Therapeutics, Inc.
- ACTM-838 / Actym Therap
ACTM-838 safely and comprehensively re-activates the immunosuppressive TME by exploiting myeloid biology intrinsic in many cancers (Section 29) - Mar 5, 2024 - Abstract #AACR2024AACR_2579;
To further understand the spatial heterogeneity in the TME across tumors, we performed multiplex immunofluorescence on patient tumor microarrays to validate tumor types with a high prevalence of myeloid populations coupled with an active adenosine pathway, which will help guide future clinical study design.In summary, we demonstrate that ACTM-838 modulates the TME and is stable and safe in animal models. Additionally, our studies recommend the prioritization of certain tumor indications for treatment with ACTM-838 in the clinic.
- ACTM-838 / Actym Therap
PK/PD biomarker analysis to assess tumor-specific enrichment and payload delivery of ACTM-838, a microbial-based immunotherapy (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_768;
Conclusions ACTM-838 is a novel immunotherapy delivering IL-15plex + eSTING payloads to phagocytic APCs, inducing a durable anti-tumor immune response, after IV dosing. IV-delivered ACTM-838 possesses a compelling safety profile in mice and primates and is currently entering clinical trials in cancer patients in Australia.
- ACTM-838 / Actym Therap
ACTM-838, a novel immunotherapy that enriches in solid tumors after IV dosing and comprehensively reverses the immunosuppressive TME to promote durable anti-tumor immunity (Section 20; Poster Board #10) - Mar 14, 2023 - Abstract #AACR2023AACR_2429;
Analyses of public RNAseq datasets from patients with primary or metastatic disease revealed cancer types with high levels of myeloid infiltration and adenosine enrichment, suggesting that ACTM-838 efficacy could provide benefit in these indications.ACTM-838 is a novel immunotherapy delivering IL-15plex + eSTING payloads to phagocytic APCs, inducing a durable anti-tumor immune response, after IV dosing. It possesses a compelling safety profile, and is currently in IND-enabling, preclinical development.
- ACTM-838 / Actym Therap
ACTM-838, a microbial-based immunotherapy that enriches in solid tumors after IV dosing, reverses the immunosuppressive TME to promote durable anti-tumor immunity, alone and in combination with anti-PD1 in mice (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1373;
IV-delivered ACTM-838 possesses a compelling safety profile in mice and primates, and is currently in IND-enabling, preclinical development. Ethics Approval All animals were used according to protocols approved by an Institutional Animal Care and Use Committee and maintained in specific pathogen-free conditions in a AAALAC accredited barrier facility.
- ACTM-838 / Actym Therap
ACTM-838: A microbial-based immunotherapy that delivers combination IL-15 + engineered STING to tumor-resident APCs After IV dosing in T-cell excluded solid tumors (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_606;
In preclinical studies, ACTM-838 promotes CD8+ T-cell mediated tumor clearance in T-cell excluded tumors and elicits durable anti-tumor immunity, and is well tolerated in primates. Based on these data, ACTM-838 was nominated for clinical development and has entered cGMP manufacturing and IND-enabling studies.